http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#Head http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#assertion http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#provenance http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#pubinfo http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#assertion http://purl.obolibrary.org/obo/DOID_13189 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_13189 http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00437 http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association http://www.w3.org/2000/01/rdf-schema#label this is not an innocuous drug it is not recommended for the treatment of asymptomatic hyperuricemia allopurinol reduces serum and urinary uric acid concentrations its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics see clinical pharmacology contraindications warnings precautions allopurinol is indicated in the management of patients with signs and symptoms of primary or secondary gout acute attacks tophi joint destruction uric acid lithiasis and or nephropathy the management of patients with leukemia lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 8 mg day in male patients and 75 mg day in female patients therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00437 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#provenance http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#pubinfo http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#sig http://purl.org/nanopub/x/hasSignature VWUN/AcNq3zQ4kcJYaq3Jt8ctCgTpRIHllQ27euKFT3FjXMbQLV9pf7CLxDfBzppV8uPZvI7RxpSQHgz4f/Rb/na2JMmFlwJdXoabvM7pPxvJOEx+oGx7Kk+bY2pQA+Yim7pzOokw8rqgIVCox6aJRuok0BnFwlpaQPIBaVokjY= http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4 http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4 http://purl.org/dc/terms/created 2021-06-13T14:45:48.675+02:00 http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAUHJdQLbvRHefGe2014Y8BMtkvmhGsDjAPpZhd_sYrC4 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs